Copelan E A, Bechtel T P, Klein J P, Klein J L, Tutschka P, Kapoor N, Featheringham N C, Avalos B R
Department of Internal Medicine, Arthur G. James Cancer Hospital and Research Institute, Ohio State University, Columbus.
Bone Marrow Transplant. 1994 Jan;13(1):87-91.
Between May 1987 and September 1989, 72 patients undergoing marrow transplantation at a single institution were randomized to receive 50 mg/kg of a commercial gammaglobulin preparation or placebo daily in four divided doses for 28 days following transplantation. Patients receiving oral gammaglobulin had significantly increased concentrations of stool IgG (p = 0.01) compared with the placebo group. There was no difference in the amount of diarrhea, frequency of GVHD, duration of hospitalization or survival in the two groups. The present study demonstrates that orally administered IgG can survive passage through the gastrointestinal tract of bone marrow transplantation recipients but there was no effect of oral administration of immunoglobulin on morbidity or mortality following bone marrow transplantation.
1987年5月至1989年9月期间，在一家机构接受骨髓移植的72例患者被随机分配，在移植后28天内每日接受50mg/kg的商业丙种球蛋白制剂或安慰剂，分四次给药。与安慰剂组相比，接受口服丙种球蛋白的患者粪便IgG浓度显著升高（p = 0.01）。两组在腹泻量、移植物抗宿主病（GVHD）发生率、住院时间或生存率方面没有差异。本研究表明，口服IgG可以在骨髓移植受者的胃肠道中存活，但口服免疫球蛋白对骨髓移植后的发病率或死亡率没有影响。
